EBR secures higher Medicare payments for WiSE cardiac pacing
CMS has finalised higher Medicare inpatient reimbursement for EBR Systems’ WiSE System, lifting base payment rates by up to 93% from 1 October 2026. The change improves the commercial payment pathway, although its financial impact will depend on procedure volumes, hospital adoption and NTAP eligibility.
- Base Medicare payments rise by approximately 58% and 93%
- Eligible procedures retain access to NTAP support of up to US$41,145
- Maximum illustrative Medicare payments reach US$77,839 and US$66,566
- New rates take effect from 1 October 2026
- Revenue impact remains dependent on adoption and procedure volumes
CMS lifts WiSE inpatient payment rates
EBR Systems, Inc. (ASX:EBR) has secured a more favourable Medicare reimbursement framework for its WiSE wireless cardiac pacing system, with higher inpatient payment rates due to take effect in the United States on 1 October 2026. The Centers for Medicare & Medicaid Services has finalised the changes under the FY2027 Inpatient Prospective Payment System Final Rule.
The key change is a reassignment of eligible WiSE procedures into higher-value Medicare Severity Diagnosis Related Groups. Procedures moving from MS-DRG 242 to 228 will see the national base payment rise from approximately US$23,233 to US$36,694, an increase of about 58%. The second reassignment, from MS-DRG 244 to 229, lifts the base payment from approximately US$13,153 to US$25,421, or about 93%.
NTAP support pushes maximum payment higher
Eligible procedures may also qualify for a New Technology Add-on Payment of up to US$41,145. On that maximum assumption, total Medicare payment could reach approximately US$77,839 for procedures classified under MS-DRG 228 and US$66,566 under MS-DRG 229.
Those figures are illustrative ceilings rather than a forecast of EBR’s revenue. Actual payments will vary according to hospital and case-specific factors, as well as the applicable CMS criteria for NTAP eligibility. The filing does not quantify expected procedure volumes, hospital uptake, revenue or profitability.
Reimbursement becomes a commercial test
CMS said the WiSE electrode is more closely aligned with leadless pacemaker procedures than conventional pacemaker procedures. That classification provides a clearer payment pathway for hospitals using the system in eligible inpatient procedures as EBR scales its US commercialisation effort.
Chief executive John McCutcheon described the final rates as a “significant reimbursement and commercial milestone” for WiSE (ASX:EBR), saying the improved payment pathway should support hospital adoption and better recognise the resources required to deliver the leadless technology. The next evidence will come not from the headline reimbursement percentages, but from how many hospitals use the pathway once it is live and whether procedure volumes convert the improved pricing into reported revenue.
Bottom Line?
The reimbursement framework is now more supportive, but EBR still needs to demonstrate that higher eligible payments translate into sustained hospital adoption and meaningful procedure volumes.
Questions in the middle?
- How quickly will hospitals begin using the revised MS-DRG payment pathway after 1 October 2026?
- What proportion of WiSE procedures will qualify for the maximum NTAP payment?
- When will EBR disclose enough procedure volume and revenue data to show the commercial effect?
